## Luisa Imberti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5957767/publications.pdf

Version: 2024-02-01

		1163117	1372567
10	529	8	10
papers	citations	h-index	g-index
1.0	1.0	1.0	0.07
10	10	10	907
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	<scp>I</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871.	1.1	140
2	Simultaneous quantification of recent thymic T-cell and bone marrow B-cell emigrants in patients with primary immunodeficiency undergone to stem cell transplantation. Clinical Immunology, 2010, 136, 217-227.	3.2	108
3	Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. Journal of Allergy and Clinical Immunology, 2007, 120, 892-899.	2.9	95
4	The Different Extent of B and T Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation and Enzyme Replacement Therapies in SCID Patients with Adenosine Deaminase Deficiency. Journal of Immunology, 2010, 185, 7713-7722.	0.8	62
5	Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2013, 11, 188.	4.4	46
6	Assessment of T-Cell receptor $\hat{l}^2$ -chain diversity by heteroduplex analysis. Human Immunology, 1996, 48, 12-22.	2.4	26
7	Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clinical Immunology, 2012, 145, 19-26.	3.2	24
8	Pre-Existing T- and B-Cell Defects in One Progressive Multifocal Leukoencephalopathy Patient. PLoS ONE, 2012, 7, e34493.	2.5	21
9	Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy. Journal of Neuroimmunology, 2014, 277, 6-12.	2.3	6
10	Long-Lasting Production of New T and B Cells and T-Cell Repertoire Diversity in Patients with Primary Immunodeficiency Who Had Undergone Stem Cell Transplantation: A Single-Centre Experience. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	1